

Source: Aktis Oncology Inc.

January 08, 2026 20:48 ET

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the pricing of its upsized initial public offering of 17,650,000 shares of its common stock at a price to the public of \$18.00 per share. In addition, Aktis has granted the underwriters a 30-day option to purchase up to an additional 2,647,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Aktis, are expected to be approximately \$318.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares of common stock are being offered by Aktis. Aktis' common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026. The offering is expected to close on January 12, 2026, subject to satisfaction of customary closing conditions.

J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen are acting as joint book-running managers for the offering.

A registration statement on Form S-1 (File No. 333-292283), as amended, relating to the offering has been filed with the Securities and Exchange Commission (the "SEC") and was declared effective on January 8, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained through the SEC's website at www.sec.gov. Alternatively, copies of the final prospectus relating to the offering, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; or TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at TDManualrequest@broadridge.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis' most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. Founded and incubated by MPM BioImpact, Aktis has developed its proprietary miniprotein

radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells, Aktis' miniprotein radioconjugates are designed to quickly clear from normal organs and tissues, thereby maximizing anticancer activity while minimizing side effects of treatment. The Aktis platform is isotope-agnostic and further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Aktis also has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis' proprietary pipeline.

Media Contact:

Sean Leous

ICR Healthcare

(646) 866-4012

Sean.Leous@icrhealthcare.com

Investor Contact:

Peter Vozzo

ICR Healthcare

(443) 213-0505

Peter.Vozzo@icrhealthcare.com